Alnylam Pharmaceuticals, Inc. (ALNY)

286.10 -9.53 (-3.22%) USD  |  NASDAQ  |  Jun 02, 16:00
286.18 +0.08 (+0.03%) After-Hours: 19:05
More

Alnylam Pharmaceuticals Research and Development Expense (% of Annual Revenues)

Research and Development Expense (% of Annual Revenues) Chart

View Research and Development Expense (% of Annual Revenues) for ALNY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (% of Annual Revenues) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (% of Annual Revenues) Range, Past 5 Years

View Research and Development Expense (% of Annual Revenues) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (% of Annual Revenues) Benchmarks

View Research and Development Expense (% of Annual Revenues) Benchmarks
Start Trial
Ionis Pharmaceuticals, Inc. Upgrade
Incyte Corp. Upgrade
BioMarin Pharmaceutical, Inc. Upgrade
BridgeBio Pharma, Inc. Upgrade
Gilead Sciences, Inc. Upgrade